Sinovac Biotech is no longer a pandemic-growth equity. It is an Antigua holding company with Beijing operations, sitting on a still-enormous pile of cash and short-term investments after a multi-year control fight and a special dividend that already moved billions off the parent. The Privy Council restored the 1Globe-backed board in early 2025, and that board then declared a fifty-five dollar special cash dividend to valid holders of record in late May of that year. Most of the declared amount has already been paid. What remains is a residual claim on a Nasdaq listing that has been frozen since February 2019, a disputed PIPE issuance from 2018, and an operating franchise that is growing abroad while still losing money at the consolidated line.
The first-half print shows the operating mix finally moving the way management has been describing. Sales rose to $147 million from the year-ago period, and overseas revenue jumped to $67 million, almost half of the top line. Varicella became the largest product and the Sabin-strain polio franchise grew with it, both lifted by international-organization orders rather than by a rebound in Chinese births. Gross margin widened and the operating loss narrowed as selling and research spending came down. The attributable loss still widened because investment income collapsed and more of the remaining loss sat in wholly owned subsidiaries that do not share the hit with minority partners. That is the real tension under the headline growth: the vaccine mix is healthier, but the residual common claim is still being shaped by cash-yield fade, allocation mechanics, and an unfinished dividend.
The forward question is not whether Sinovac can print another mid-teens sales increase. It is whether the remaining special-dividend payable ever reaches valid holders, whether the listing ever becomes a real market again, and whether overseas tenders plus a late-stage pipeline can replace the investment income that used to paper over an operating loss. The last Nasdaq print is a stale mid-single-digit figure that implies only a few hundred million of equity value against several billion of cash and investments. That gap is the entire case. It is also the entire risk, because trapped cash is not the same thing as a collectible residual claim.